Internet Pioneer In...
Health Care: Drugs
Compugen Ltd. (CGEN: NASDAQ)
$3.41 -0.12 | -3.40%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.72 | 0.58 | 0.98 |
| Price to Sales (TTM) | 0.00 | 4.62 | 1.42 |
| Price to Book (MRQ) | 5.57 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 5.57 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -8.50 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -12.70 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -20.40 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 12.00 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 12.30 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -338.52 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | n.a. | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -43.80 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -36.20 | 2.20 | 2.50 |
| Return on Investment (TTM) | -66.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -46.50 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 0.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -364,692.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 0.00 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with CGEN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Bargain Biotech Stocks
- Userdesignbydiana Portfolio 1
- Userraveha1 Portfolio 1
- ContributorBiotech Short Squeezes
- UserSUPRATRADE-QUANTUM STARDUST 8
- UserHumelor Portfolio 1
Latest CGEN Headlines from TheStreet
- 7 Stocks Under $10 Soaring Higher 05.24.12 | 12:05 pm
- 5 Bargain Biotech Stocks 01.13.11 | 05:01 pm
- Maguire Properties, Compugen: Midday Volume Plays 05.11.10 | 11:05 am
- eOn Communications, Compugen: Early Volume Plays 03.16.10 | 09:03 am
- Pluristem Therapeutics, Compugen: Early Volume Plays 03.02.10 | 09:03 am
- Array BioPharma, Sterling Financial: Early Volume Plays 02.02.10 | 09:02 am
- Biotech's Movers & Shakers 2009: BioBuzz 01.04.10 | 09:01 am
- Compugen, Flotek: Early Volume Plays 01.04.10 | 07:01 am
- China BAK, Compugen: Early Volume Plays 12.30.09 | 08:12 am
- Compugen, Sinovac: Early Volume Plays 12.28.09 | 08:12 am
Press Releases for CGEN
- Dr. Mary Haak-Frendscho, Chairperson Of Compugen’s US Subsidiary, To Give Keynote Address At China Pharmaceutical R&D Summit - Business Wire 04.23.12 | 07:04 am
- Compugen First Quarter 2012 Conference Call Scheduled For Tuesday, May 1, 2012 At 10:00 AM EST - Business Wire 04.23.12 | 07:04 am
- Compugen Presents Prediction Based Discovery Strategy At “Targets And Strategies For Drug Discovery” Conference - Business Wire 02.27.12 | 07:02 am
- Compugen Cancer Target Results Demonstrate Significant Potential For Cancer Immunotherapy - Business Wire 02.02.12 | 06:02 am
- Compugen To Broaden And Accelerate Monoclonal Antibody Program For Oncology And Immunology - Business Wire 12.20.11 | 10:12 am
- BioLineRx To Develop And Commercialize Novel Peptide Drug Candidates Discovered By Compugen - Business Wire 12.13.11 | 06:12 am
- Compugen Presents Predictive Drug Target Discovery Platform At European Antibody Conference - Business Wire 11.30.11 | 07:11 am
- Www.discoverx.com - Business Wire 11.29.11 | 07:11 am
- Compugen Reports Third Quarter 2011 Financial Results - Business Wire 11.08.11 | 07:11 am
- Compugen's CGEN-15001 Pre-Clinical Data Presented At International Conference On Immune Tolerance - Business Wire 10.25.11 | 07:10 am
Partner Headlines for CGEN
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- Compugen: On the Road to Breakthroughs - Seeking Alpha 05.12.10 | 03:05 am
